以胸骨或纵隔受累起病的乳腺癌患者根治性治疗结局
单中心回顾性队列研究纳入2005至2014年新发转移性乳腺癌患者,原发队列为转移限于纵隔/胸骨并接受根治性治疗者(n=35),另设IIIC期根治性治疗队列(n=244)、纵隔/胸骨姑息队列(n=14)及其他新发IV期姑息队列(n=1185),中位随访50个月。纵隔/胸骨根治队列5年局部区域无复发生存率85%、无复发生存率52%、总生存率63%,校正后与IIIC期队列无统计学显著差异,无复发生存优于纵隔/胸骨姑息队列,总生存优于新发IV期姑息队列。
要点
- 纵隔/胸骨根治队列5年局部区域无复发生存率85%、无复发生存率52%、总生存率63%。
- 校正后纵隔/胸骨根治队列与IIIC期队列的局部区域无复发生存、无复发生存及总生存均无统计学显著差异。
- 纵隔/胸骨姑息队列无复发生存较根治队列差(HR 2.29,95%CI 1.05-5.00,P=.04),新发IV期姑息队列总生存最差(HR 2.61,95%CI 1.50-4.53,P<.001)。
核心结论
- 对于部分胸骨和/或纵隔转移的乳腺癌患者,以化疗、手术和放疗行根治性治疗可获得与IIIC期疾病相似的结局,并优于以姑息意图治疗的新发IV期乳腺癌。
研究设计与样本
- 单中心回顾性队列研究,纳入2005至2014年新发转移性乳腺癌患者,原发队列中位随访50个月。
- 原发队列为转移限于纵隔/胸骨并接受根治性治疗者(n=35);另设IIIC期根治性治疗队列(n=244)、纵隔/胸骨姑息队列(n=14)及其他新发IV期姑息队列(n=1185)。
- 采用Kaplan-Meier法计算局部区域无复发生存(LRRFS)、无复发生存(RFS)和总生存(OS),Cox多变量模型校正分子亚型、年龄和种族后比较各队列生存结局。
主要发现
- 纵隔/胸骨根治队列5年LRRFS为85%,RFS为52%,OS为63%。
- 校正后,IIIC期队列与纵隔/胸骨根治队列(参照)相比,LRRFS(HR 0.39,95%CI 0.13-1.13,P=.08)、RFS(HR 0.87,95%CI 0.50-1.49,P=.61)和OS(HR 0.79,95%CI 0.44-1.43,P=.44)均无统计学显著差异。
- 纵隔/胸骨姑息队列RFS较纵隔/胸骨根治队列差(HR 2.29,95%CI 1.05-5.00,P=.04)。
- 新发IV期姑息队列OS最差(HR 2.61,95%CI 1.50-4.53,P<.001)。
临床怎么用
- 原文结论认为,对于部分胸骨和/或纵隔转移的乳腺癌患者,以化疗、手术和放疗行根治性治疗可获得与IIIC期疾病相似的结局,并优于以姑息意图治疗的新发IV期乳腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal treatment of patients diagnosed with de novo metastatic breast cancer limited to the mediastinum or sternum has never been delineated. Herein, we sought to determine the efficacy of multimodality treatment, including metastasis-directed radiation therapy, in curing patients with this presentation. METHODS AND MATERIALS: This is a single-institution retrospective cohort study of patients with de novo metastatic breast cancer treated from 2005 to 2014, with a 50-month median follow-up for the primary cohort. The primary patient cohort had metastasis limited to the mediastinum/sternum treated with curative intent (n = 35). We also included a cohort of patients with stage IIIC disease treated with curative intent (n = 244). Additional groups included a mediastinal/sternal palliative cohort (treatment did not include metastasis-directed radiation therapy; n = 14) and all other patients with de novo stage IV disease (palliative cohort; n = 1185). The primary study outcomes included locoregional recurrence-free survival (LRRFS), recurrence-free survival (RFS), and overall survival (OS), which were calculated using the Kaplan-Meier method. Cox multivariable models compared survival outcomes across treatment cohorts adjusted for molecular subtype, age, and race. RESULTS: For the mediastinal/sternal curative-intent cohort, 5-year LRRFS was 85%, RFS was 52%, and OS was 63%. After adjustment, there was no statistically significant difference in LRRFS (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.13-1.13; P = .08), RFS (HR, 0.87; 95% CI 0.50-1.49; P = .61), or OS (HR, 0.79; 95% CI 0.44-1.43; P = .44) between the stage IIIC cohort and the mediastinal/sternal curative-intent cohort (referent). In contrast, RFS was worse for the mediastinal/sternal palliative cohort (HR, 2.29; 95% CI 1.05-5.00; P = .04). OS was worst for the de novo stage IV palliative cohort (HR, 2.61; 95% CI 1.50-4.53; P < .001). CONCLUSIONS: For select patients presenting with breast cancer metastatic to the sternum and/or mediastinum, curative-intent treatment with chemotherapy, surgery, and radiation yields outcomes similar to those of stage IIIC disease and superior to de novo stage IV breast cancer treated with palliative intent.
引用
- Christopherson K, Lei X, Barcenas C, et al. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851348. doi:10.1016/j.ijrobp.2019.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。